Regeneron Pharmaceuticals Inc (REGN) — Cash Flow-to-Debt Ratio
Regeneron Pharmaceuticals Inc (REGN) has a Cash Flow-to-Debt Ratio of 0.11x as of March 2026, meaning its operating cash flow of $1.08 Billion could theoretically repay 0% of its total liabilities ($9.45 Billion) in one year. See REGN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Regeneron Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1991–2025)
Historical debt coverage capacity for Regeneron Pharmaceuticals Inc across 35 annual periods. Also explore Regeneron Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Regeneron Pharmaceuticals Inc (1991–2025)
Year-by-year debt coverage analysis for Regeneron Pharmaceuticals Inc. For market capitalisation and broader financial context, see Regeneron Pharmaceuticals Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.54x | $4.98 Billion | $9.30 Billion | ▲ +1.8% |
| 2024 | 0.53x | $4.42 Billion | $8.41 Billion | ▼ -18.6% |
| 2023 | 0.65x | $4.59 Billion | $7.11 Billion | ▼ -15.6% |
| 2022 | 0.77x | $5.01 Billion | $6.55 Billion | ▼ -27.9% |
| 2021 | 1.06x | $7.08 Billion | $6.67 Billion | ▲ +149.1% |
| 2020 | 0.43x | $2.62 Billion | $6.14 Billion | ▼ -34.8% |
| 2019 | 0.65x | $2.43 Billion | $3.72 Billion | ▼ -11.3% |
| 2018 | 0.74x | $2.20 Billion | $2.98 Billion | ▲ +47.8% |
| 2017 | 0.50x | $1.31 Billion | $2.62 Billion | ▼ -15.3% |
| 2016 | 0.59x | $1.49 Billion | $2.52 Billion | ▼ -13.6% |
| 2015 | 0.68x | $1.33 Billion | $1.95 Billion | ▲ +20.3% |
| 2014 | 0.57x | $752.43 Million | $1.33 Billion | ▼ -3.9% |
| 2013 | 0.59x | $588.60 Million | $998.94 Million | ▲ +759.5% |
| 2012 | -0.09x | $-74.61 Million | $835.11 Million | ▲ +47.2% |
| 2011 | -0.17x | $-141.68 Million | $837.85 Million | ▼ -198.6% |
| 2010 | 0.17x | $96.34 Million | $561.62 Million | ▲ +181.8% |
| 2009 | -0.21x | $-72.23 Million | $344.44 Million | ▲ +40.9% |
| 2008 | -0.35x | $-89.09 Million | $251.19 Million | ▼ -716.7% |
| 2007 | 0.06x | $27.37 Million | $475.99 Million | ▼ -8.2% |
| 2006 | 0.06x | $23.07 Million | $368.47 Million | ▲ +164.0% |
| 2005 | -0.10x | $-30.30 Million | $309.50 Million | ▼ -68.2% |
| 2004 | -0.06x | $-16.91 Million | $290.56 Million | ▼ -224.4% |
| 2003 | -0.02x | $-6.13 Million | $341.91 Million | ▲ +96.0% |
| 2002 | -0.45x | $-110.52 Million | $245.59 Million | ▼ -79.8% |
| 2001 | -0.25x | $-57.32 Million | $229.04 Million | ▲ +76.6% |
| 2000 | -1.07x | $-27.91 Million | $26.14 Million | ▼ -112.7% |
| 1999 | -0.50x | $-13.80 Million | $27.50 Million | ▼ -26.4% |
| 1998 | -0.40x | $-10.20 Million | $25.70 Million | ▼ -91.9% |
| 1997 | -0.21x | $-6.10 Million | $29.50 Million | ▲ +68.7% |
| 1996 | -0.66x | $-20.30 Million | $30.70 Million | ▲ +5.9% |
| 1995 | -0.70x | $-18.20 Million | $25.90 Million | ▲ +7.1% |
| 1994 | -0.76x | $-20.50 Million | $27.10 Million | ▲ +51.7% |
| 1993 | -1.57x | $-30.10 Million | $19.20 Million | ▲ +2.5% |
| 1992 | -1.61x | $-17.20 Million | $10.70 Million | ▼ -84.4% |
| 1991 | -0.87x | $-6.80 Million | $7.80 Million | — |